论文部分内容阅读
目的:评价复方丹参滴丸联合他汀类治疗冠心病的临床疗效。方法:检索Medline、Pub Med、CNKI、万方数据库、CBM数据库,查找2007~2016年近10年公开发表的关于复方丹参滴丸联合他汀类治疗冠心病随机对照临床研究,根据纳入与排除标准对文献进行筛选,提取数据资料,并对纳入研究的方法学质量进行评价,运用Rev Man 5.3软件进行Meta分析。结果:复方丹参滴丸组对冠心病的心绞痛改善[OR=3.84,95%CI(2.56,5.77),P<0.00001],改善心电图效果[OR=2.83,95%CI(2.05,3.92),P<0.00001]。降低胆固醇[WMD=1.75,95%CI(1.65,1.76),P<0.00001],降低三酰甘油[WMD=0.60,95%CI(0.56,0.63),P<0.00001],降低低密度脂蛋白[WMD=1.27,95%CI(1.19,1.34),P<0.00001],降低血小板聚集率[WMD=12.50,95%CI(11.48,13.51),P<0.00001],降低血浆黏度[WMD=0.80,95%CI(0.76,0.84),P<0.00001]。结论:复方丹参滴丸联合他汀类能明显改善冠心病患者心绞痛症状、提高心电图疗效、降低血脂、改善血液流变学,且优于常规西药治疗,具有较高的安全性。
Objective: To evaluate the clinical efficacy of compound Danshen dripping pills and statins in the treatment of coronary heart disease. Methods: A randomized controlled clinical trial of Fufang Danshen Diwan combined with statins in the treatment of coronary heart disease (CHD) was searched in the past 10 years from 2007 to 2016. According to the inclusion and exclusion criteria, the data of Medline, Pub Med, CNKI, Wanfang database and CBM database were searched. The literature was screened, data extracted, quality of methodologies included in the study evaluated, and Meta-analysis performed using Rev Man 5.3 software. Results: The improvement of angina pectoris in CHD group (OR = 3.84,95% CI 2.56, 5.77, P <0.00001) and improvement of ECG (OR = 2.83, 95% CI 2.05, 3.92) <0.00001]. Lowering the triglyceride [WMD = 0.60, 95% CI (0.56, 0.63), P <0.00001] and lowering the LDL cholesterol [WMD = 1.75,95% CI 1.65,1.76, P <0.00001] WMD = 1.27,95% CI (1.19,1.34), P <0.00001], lower platelet aggregation rate [WMD = 12.50,95% CI (11.48,13.51), P <0.00001] % CI (0.76, 0.84), P <0.00001]. Conclusion: Compound Danshen dripping pills combined with statins can significantly improve angina pectoris in patients with coronary heart disease, improve ECG efficacy, reduce blood fat, improve blood rheology, and is superior to conventional western medicine with high safety.